recombinant adenoviral serotype 5 vector vaccine
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2009 (NCT00865566)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human adenovirus type 5Immunity, active
Human adenovirus type 5 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- recombinant adenoviral serotype 5 vector vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00865566 | Phase 2 | May 1, 2009 | Columbia University, HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Columbia University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| HIV Vaccine Trials Network | Academic/Hospital | 1 | 0 | 1 | 2009 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2009 |
3 organizations
Page 1 / 1